GRI (GRI Bio Corp) Net earnings per share (EPS TTM)
GRI Bio, Inc. (GRI) is developing innovative NKT therapy to combat chronic inflammation. The annual EPS (TTM) growth statistics visualize profit dynamics, where the metric level stands at 93.60. The company's technological foundation enables the seamless scaling of new formulas. However, the lack of stable revenue and the dependence of share prices on clinical trial outcomes create significant financial risks for investors.
GRI (GRI Bio Corp): analytical breakdowns and indicator data
- market value and analyst target forecast:
- business market valuation indicators:
- shareholders' equity book value data:
- debt and liquidity data:
Debt to Capital Ratio GRI Bio, Inc.|GRI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital GRI Bio Corporation|GRI - Company Aggregate Debts|Debts to Net Assets GRI Bio Inc|GRI - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings GRI Bio|Quick Liquidity gribio.com
- earnings and valuation multiples information:
GRI - Net Profit|Company Profit Forecast GRI Bio, Inc.|GRI - Price to Earnings Ratio|Projected Price to Earnings Ratio GRI Bio Inc|GRI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation GRI Bio Inc|GRI - Operating profit EBITDA|Net earnings per share for the last four quarters GRI Bio|GRI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months gribio.com|GRI - Earnings growth in current year|Expected earnings per share growth for next year GRI Bio, Inc.
- sales and revenue indicators:
Fundamental company valuation:GRI (gribio.com)
Comparing profit dynamics across assets allows an investor to assess the efficiency of capital management. This metric compares the total net earnings per share over the last four quarters with the same period last year. For GRI Bio, Inc. (GRI), this reflects financial stability during the expansion of clinical trials for the GRI-0621 drug. Growth in this indicator confirms the successful monetization of the NKT inhibitor pipeline. By analyzing the 12-month history of YoY EPS changes, one can identify risks of margin compression.
Direct competitors
argenx.com (ARGX) - Net earnings per share for the last 12 months|BNTX (BioNTech) - Net earnings per share for the last 12 months|Abivax Corp (ABVX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months ADMA Bio|Earnings per share for the last 12 months PTGX (Protagonist Corp)|Net earnings per share (EPS TTM) IMVT|KNSA - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) GRFS (Grifols)|Net earnings per share for the trailing year Adaptive Biotech|CLDX - Earnings per share for the last twelve months|Earnings per share for the trailing year AUPH (Aurinia Corp)|BCRX: Net earnings per share (EPS TTM)|VERA - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months DNTH|PHVS: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ABCL|Earnings per share for the last twelve months TRML (Tourmaline)|Net earnings per share (EPS TTM) PGEN (Precigen, Inc.)|Net earnings per share for the last four quarters pharming.com (PHAR)|NKTR - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Upstream Bio, Inc.|ZBIO (Zenas Biopharma, Inc.) - Net earnings per share for the last 12 months|Immunome Bio - Earnings per share for the trailing year|GOSS (Gossamer Bio, Inc.) - Net earnings per share (EPS TTM)|kalvista.com (KALV) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Septerna (SEPN)|Pieris Pharma - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SVRA (Savara Corp)|RIGL - Net earnings per share for the last 12 months|ANAB: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters astriatx.com ATXS|ENGN: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year rapt.com RAPT|Earnings per share for the last twelve months Aerovate Therapeutics, Inc.|ACRS: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KYTX|Net earnings per share for the last four quarters tizianalifesciences.com|Earnings per share for the last twelve months Cabaletta Bio CABA|VTYX (Ventyx Biosciences Inc.) - Earnings per one share for the last 12 months|Theratechnologies Inc - Net earnings per share (EPS TTM)|Earnings per share for the trailing year AVTX (Avalo Therapeutics Inc)|ELDN: Net earnings per share (EPS TTM)|agenusbio.com (AGEN) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Climb Bio|ZURA: Earnings per share for the trailing year|Earnings per share for the last twelve months aTyr (ATYR)|Net earnings per share for the last 12 months adagene.com ADAG|Net earnings per share (EPS TTM) IMA (Ikena Oncology)|Net earnings per share (EPS TTM) Shattuck Labs Inc STTK|EQ: Net earnings per share for the last 12 months|Earnings per share for the trailing year CNTB (Connect Biopharma)|IMUX: Net earnings per share (EPS TTM)|ATRA - Net earnings per share for the last four quarters|Earnings per share for the last twelve months InflaRx NV|Net earnings per share for the last 12 months x4pharma.com (XFOR)|Earnings per share for the last twelve months Adicet Bio (ACET)|Net earnings per share for the last 12 months celularity.com CELU|INmune Bio Corp - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Barinthus Biotherapeutics Corp BRNS|KZR - Earnings per share for the last twelve months|SABS (sabbiotherapeutics.com) - Earnings per share for the last 12 months|AKTX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Enlivex Therapeutics Ltd. (ENLV)|QTTB (Q32 Bio Inc) - Net earnings per share (EPS TTM)|GOVX - Net earnings per share for the trailing year|Earnings per share for the last twelve months Edesa Biotech, Inc. (EDSA)|IBIO (ibioinc.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) CARM (Carisma Therapeutics Inc.)|Net earnings per share for the last four quarters XTL Biopharmaceuticals Ltd (XTLB)|BOLT: Net earnings per share for the last 12 months|Earnings per share for the trailing year HCWB (HCW Biologics Inc.)|APVO: Net earnings per share (EPS TTM)|AIM (aimimmuno.com) - Earnings per share for the last twelve months|ADTX (Aditxt Inc.) - Net earnings per share (EPS TTM)|XORTX Therapeutics Inc (XRTX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months ReShape Lifesciences (HIND)|REVB - Net earnings per one share for the last twelve months|Indaptus Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year SCNI|CalciMedica Corp - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Affimed AFMD|allakos.com (ALLK) - Earnings per share for the last twelve months|Earnings per share for the last 12 months HOOK|IGMS (IGM Biosciences Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months iteostherapeutics.com (ITOS)|Net earnings per share for the last 12 months OCEA (Ocean Biomedical)|Net earnings per share for the last four quarters TC BioPharm (Holdings) Plc|Net earnings per share (EPS TTM) THRD (Third Harmonic Bio, Inc)
